Home/Filings/4/0001209191-21-070352
4//SEC Filing

Morosini Deborah 4

Accession 0001209191-21-070352

CIK 0001678660other

Filed

Dec 16, 7:00 PM ET

Accepted

Dec 17, 5:20 PM ET

Size

15.2 KB

Accession

0001209191-21-070352

Insider Transaction Report

Form 4
Period: 2021-12-15
Morosini Deborah
EVP, Chief of Clinical Affairs
Transactions
  • Exercise/Conversion

    Common Stock

    2021-12-15$12.85/sh+25,735$330,69529,195 total
  • Sale

    Common Stock

    2021-12-15$13.00/sh28,751$373,763444 total
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2021-12-153,0161,307 total
    Exercise: $1.89Exp: 2030-03-26Common Stock (3,016 underlying)
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2021-12-15882195,163 total
    Exercise: $12.85Exp: 2030-09-01Common Stock (882 underlying)
  • Exercise/Conversion

    Common Stock

    2021-12-15$1.89/sh+3,016$5,7003,460 total
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2021-12-1524,85374,575 total
    Exercise: $12.85Exp: 2030-09-01Common Stock (24,853 underlying)
Footnotes (4)
  • [F1]The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  • [F2]The stock option is fully vested.
  • [F3]The stock option vests as to 25% of the total shares monthly beginning on September 24, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
  • [F4]The stock option vests as to 25% of the total shares monthly beginning on July 27, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

Issuer

Prelude Therapeutics Inc

CIK 0001678660

Entity typeother

Related Parties

1
  • filerCIK 0001824625

Filing Metadata

Form type
4
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 5:20 PM ET
Size
15.2 KB